Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189

Introduction: The aim of this study was to evaluate the efficacy of pemetrexed and platinum plus pembrolizumab by baseline tumor burden. Methods: A total of 616 patients in the intention-to-treat population of the KEYNOTE-189 study were included in this analysis. Baseline tumor burden subgroups were...

Full description

Bibliographic Details
Main Authors: Shirish Gadgeel, MD, Jhanelle E. Gray, MD, Maria Teresa Rizzo, MD, Patrick Peterson, PhD, Jong Seok Kim, MD, Delvys Rodríguez-Abreu, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:JTO Clinical and Research Reports
Subjects:
Metastatic nonsquamous non–small cell lung cancer
Pemetrexed
Pembrolizumab
Tumor burden
Immune checkpoint inhibitors
Chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001138

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001138

Similar Items